Bicycle Therapeutics & Oxurion: Positive Topline Phase 1 Results with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME)

01 July 2019

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME). THR-149 has been developed in partnership with Bicycle Therapeutics […]

Continue Reading

Nuvaira: Revolutionary therapy that blasts 80°C radiofrequency into defective lung nerves could help thousands of sufferers with severe asthma

06 June 2019

Nuvaira deploys a ground-breaking therapy called targeted lung denervation.  It’s based on the discovery that a faulty nerve that runs from the brain to the lungs may be partly to blame for asthma flare-ups. For many years, the illness was thought to be due solely to the immune system overreacting to allergens – such as […]

Continue Reading

Instarem Raises a New $41 Million Series C

19 March 2019

Instarem is a Singapore-based provider of innovative cross-border payment solution for retail and enterprise clients. Cross-border money transfers and transactions have been a costly and cumbersome process, with senders unable to ascertain the total cost and time needed to complete the process. Instarem streamlines the process of sending and settling cross-border payment through its technology […]

Continue Reading

Vertex Growth invests in PerimeterX’s $43 million equity financing round

12 February 2019

PerimeterX develops a scalable, behaviour-based bot protection solution with predictive detection for web, mobile and APIs. Its core product, PX Bot Defender, offers “bot protection-as-a-service,” safeguarding online services from account takeover attacks, scraping, checkout abuse, carding attacks and marketing fraud. To stop bot attacks, PerimeterX detects anomalies in user behaviour by approaching detection on three […]

Continue Reading

Vertex Growth invests in Nuvaira’s $79 million equity financing round

11 February 2019

Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, is developing the Nuvaira Lung Denervation System to address chronic lung diseases by treating the overactive airway nerves with Targeted Lung Denervation (TLD). Nuvaira’s Lung Denervation System is a novel catheter-based medical device, which has the potential to fill a large and […]

Continue Reading